A Randomised, Double Blind, Placebo-Controlled, Parallel-Group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2015
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 31 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 28 Aug 2009 Actual patient number (84) added as reported by ClinicalTrials.gov.